Three lawsuits against makers of the drug Lidoderm, consolidated into one, have reached a settlement deal of $104.75 million.
These antitrust, patent infringement, and anticompetitive class action lawsuits resolve allegations against Endo Pharmaceuticals Inc., Teikoku Pharma USA Inc., Teikoku Seiyaku Co. Ltd., Actavis Inc., Watson Labratories Inc., Actavis plc, Anda Inc., Anda Pharmaceuticals Inc. and Valmed Pharmaceuticals.
According to the lawsuit, Endo and Teikoku paid Watson, Actavis, Anda, and Valmed to delay the launch of the generic version of Lidoderm- violating many Laws- forcing consumers to pay more for the brand-name and the generic Lidoderm than they would have paid otherwise.
Class members include all United States citizens who:
- Are located in Arizona, California, Florida, Kansas, Maine, Massachusetts, Minnesota, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, South Dakota, Tennessee, West Virginia or Wisconsin;
- Purchased the name-brand or generic Lidoderm for consumption by themselves, a family member, or by their insureds, plan participants or beneficiaries; and/or
- Paid for some or all of the purchase price of brand-name Lidoderm between Aug. 23, 2012 and Sept. 14, 2013 and/or AB-rated generic Lidoderm between Sept. 15, 2013 and Aug. 1, 2014.
The deadline to file a claim is October 1, 2018.
For more information, please contact the Pirl team at (650) 762-8545 or fill out the form below.
*****A VITAL NOTE FROM THE PIRL TEAM: As we report on any medical product/medication case - NEVER STOP OR ALTER A MEDICAL PROGRAM OR COURSE OF MEDICATION WITHOUT CONSULTING YOUR(S) OR A PHYSICIAN.*****